Calendario›SNY›Dupilumab · GLOBOSPIN

Dupilumab · GLOBOSPIN

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

Ensayo de Sanofi en Prurigo nodular.

Fase: no aplica
Estado: En marcha, sin reclutar
Participantes: 100
Centros: 49
Fin del objetivo primario: sep 2026

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en dic 2023.

Qué mide

Frequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment (del registro, en inglés) (en el inicio)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

Más ensayos de SNY

Ensayo	Fase	Estado	Lectura de resultados
Avalglucosidase alfa · Mini-COMET	Fase 2	En marcha, sin reclutar	sep 2019 (real)
Yellow fever vaccine	Fase 2	En marcha, sin reclutar	may 2022 (real)
Yellow fever vaccine · VYF02	Fase 2	En marcha, sin reclutar	jun 2022 (real)
SAR441344 IV	Fase 2	En marcha, sin reclutar	sep 2022 (real)
Meningococcal Polysaccharide	Fase 3	En marcha, sin reclutar	mar 2023 (real)
Isatuximab IV · IRAKLIA	Fase 3	En marcha, sin reclutar	nov 2024 (real)

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05991323), actualizada en sep 2025.